Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esophagus Disorder Clear all
Recruiting Phase 1Phase 2 Interventional

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493
View directory record Official record
Conditions
Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
AZD5863, AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome

NCT02513784
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Barrett's Esophagus, Reflux Esophagitis
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 17, 2026, 3:33 AM EDT
Recruiting Phase 1 Interventional

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

NCT06657144
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 17, 2026, 3:33 AM EDT
Terminated Not applicable Interventional

An Evaluation of the Medtronic Gatekeeper System in the Treatment of SUBJECTS With Gastroesophageal Reflux Disease (GERD)

NCT00200044
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Gatekeeper Reflux Repair System
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2009 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule

NCT02445014
View directory record Official record
Conditions
Healthy, Barrett's Esophagus, Gastric Acid Reflux
Interventions
MGH SECM Imaging Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction

NCT01401699
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Optical Frequency Domain Imaging (OFDI)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 17, 2026, 3:33 AM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia

NCT00376506
View directory record Official record
Conditions
Chronic Dysphagia, Multiple Sclerosis, Parkinson Disease
Interventions
Neurostimulation device for dysphagia, External vibrotactile device
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

NCT01490749
View directory record Official record
Conditions
Esophageal Cancer, Neoplasms, Esophageal
Interventions
RAD001, XELOX, Carboplatin, Radiation
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)

NCT02722148
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

NCT00390416
View directory record Official record
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 17, 2026, 3:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

NCT05572684
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

NCT00130689
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, Neoplasm Metastasis
Interventions
Cetuximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

NCT03008278
View directory record Official record
Conditions
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Olaparib, Ramucirumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
32
States / cities
Corona, California • Duarte, California • Lancaster, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 17, 2026, 3:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738
View directory record Official record
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 17, 2026, 3:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

NCT05914116
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants

NCT00131248
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Metaclopramide, Ranitidine, placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Month to 6 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 17, 2026, 3:33 AM EDT
Recruiting No phase listed Observational

Clinical Outcomes, Safety, and Effectiveness of Speedboat UltraSlim™ in Per-Oral Endoscopic Myotomy (POEM)

NCT07496840
View directory record Official record
Conditions
Esophageal Motility Disorders, Achalasia
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

NCT01885195
View directory record Official record
Conditions
Solid Tumor and Hematologic Malignancies
Interventions
MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
68
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

NCT00909402
View directory record Official record
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
BMS-833923, Cisplatin, Capecitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445
View directory record Official record
Conditions
Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions
Educational Video and QPL List, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 17, 2026, 3:33 AM EDT
Completed Not applicable Interventional

Pilot Study of Esocheck in Eosinophilic Esophagitis

NCT04311970
View directory record Official record
Conditions
Eosinophilic Esophagitis, Diagnoses Disease
Interventions
EsoCheck
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 17, 2026, 3:33 AM EDT
Completed No phase listed Observational

Study of Fetal Swallowing

NCT00004566
View directory record Official record
Conditions
Deglutition Disorder, High Risk Pregnancy
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 3:33 AM EDT
Withdrawn Phase 2 Interventional

Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus

NCT01301495
View directory record Official record
Conditions
Esophageal Cancer
Interventions
HANAROSTENT TM covered Esophageal Stent
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 17, 2026, 3:33 AM EDT